Approved Sickle Cell Drug Fails to Beat Placebo in Trial

You May Be Interested In:2025 Stanley Cup first-round betting guide: Best bets and Conn Smythe predictions



(MedPage Today) — Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.
Adjusted annualized rate of vaso-occlusive crises leading to healthcare visits was 2.49 with the standard…

share Paylaş facebook pinterest whatsapp x print

Similar Content

Dry January: Should Doctors Make It Year-Round?
Dry January: Should Doctors Make It Year-Round?
HIMSSCast: Nurses want AI to enhance patient interactions
HIMSSCast: Nurses want AI to enhance patient interactions
Can rural hospitals face cybersecurity risks alone?
Can rural hospitals face cybersecurity risks alone?
Neuro Break over a computer rendering of neurons.
Ozempic for Alzheimer’s? What Drives Brain Age; Primary Care Alzheimer’s Guideline
Project to launch Vietnam's first AI virtual hospital announced
Project to launch Vietnam’s first AI virtual hospital announced
UV Radiation and MCPyV Account for Most Merkel Cell Cases
UV Radiation and MCPyV Account for Most Merkel Cell Cases
The News Link | © 2025 | News